Compounds > 10-propargyl-10-deazaaminopterin
Page last updated: 2024-09-04

10-propargyl-10-deazaaminopterin and bortezomib

10-propargyl-10-deazaaminopterin has been researched along with bortezomib in 7 studies

Compound Research Comparison

Studies
(10-propargyl-10-deazaaminopterin)		Trials
(10-propargyl-10-deazaaminopterin)		Recent Studies (post-2010)
(10-propargyl-10-deazaaminopterin)		Studies
(bortezomib)		Trials
(bortezomib)		Recent Studies (post-2010) (bortezomib)
11921856,8688604,753

Protein Interaction Comparison

ProteinTaxonomy10-propargyl-10-deazaaminopterin (IC50)bortezomib (IC50)
Proteasome subunit beta type-11Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 11Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 12Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 14Homo sapiens (human)0.5335
Proteasome subunit alpha type-7Homo sapiens (human)0.3213
Histone deacetylase 3Homo sapiens (human)1.18
26S proteasome non-ATPase regulatory subunit 3Homo sapiens (human)0.5335
Cathepsin GHomo sapiens (human)1.81
Lysosomal protective proteinHomo sapiens (human)9.2
26S proteasome regulatory subunit 6AHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p105 subunitHomo sapiens (human)0.085
Proteasome subunit beta type-1Homo sapiens (human)0.2149
ChymaseHomo sapiens (human)1.19
Proteasome subunit alpha type-1Homo sapiens (human)0.3213
Proteasome subunit alpha type-2Homo sapiens (human)0.3213
Proteasome subunit alpha type-3Homo sapiens (human)0.3213
Proteasome subunit alpha type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-8Homo sapiens (human)0.1681
Proteasome subunit beta type-8Mus musculus (house mouse)0.0168
Proteasome subunit beta type-9Homo sapiens (human)0.2059
Proteasome subunit alpha type-5Homo sapiens (human)0.3213
Proteasome subunit beta type-4Homo sapiens (human)0.3213
Proteasome subunit beta type-6Homo sapiens (human)0.2842
Proteasome subunit beta type-5Homo sapiens (human)0.1407
26S proteasome regulatory subunit 7Homo sapiens (human)0.5335
Lon protease homolog, mitochondrialHomo sapiens (human)0.183
Proteasome subunit beta type-10Homo sapiens (human)0.5359
26S proteasome regulatory subunit 6BHomo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 8Homo sapiens (human)0.5335
Proteasome subunit beta type-3Homo sapiens (human)0.3213
Proteasome subunit beta type-2Homo sapiens (human)0.9297
26S proteasome non-ATPase regulatory subunit 7Homo sapiens (human)0.5335
26S proteasome non-ATPase regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome complex subunit SEM1Homo sapiens (human)0.5335
Proteasome subunit alpha type-6Homo sapiens (human)0.3213
26S proteasome regulatory subunit 4Homo sapiens (human)0.5335
26S proteasome regulatory subunit 8Homo sapiens (human)0.5335
26S proteasome regulatory subunit 10BHomo sapiens (human)0.5335
Nuclear factor NF-kappa-B p100 subunit Homo sapiens (human)0.085
Transcription factor p65Homo sapiens (human)0.085
26S proteasome non-ATPase regulatory subunit 2Homo sapiens (human)0.5335
Histone deacetylase 1Homo sapiens (human)0.62
26S proteasome non-ATPase regulatory subunit 6Homo sapiens (human)0.5335
Proteasomal ubiquitin receptor ADRM1Homo sapiens (human)0.5335
ATP-dependent Clp protease proteolytic subunitStaphylococcus aureus subsp. aureus NCTC 83255.3
NACHT, LRR and PYD domains-containing protein 3 Mus musculus (house mouse)0.0407
Proteasome subunit alpha-type 8Homo sapiens (human)0.3213
Histone deacetylase 2Homo sapiens (human)0.8
Proteasome subunit beta type-7Homo sapiens (human)0.3213
26S proteasome non-ATPase regulatory subunit 1Homo sapiens (human)0.5335
Histone deacetylase 8Homo sapiens (human)0.072
26S proteasome non-ATPase regulatory subunit 13Homo sapiens (human)0.5335

Research

Studies (7)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's7 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
O'Connor, OA1
Marchi, E; O'Connor, OA; Paoluzzi, L; Scotto, L; Seshan, VE; Zain, JM; Zinzani, PL1
Mangone, M; Marchi, E; O'Connor, OA; Zullo, K1
Duvic, M1
Berube, C; Coutré, SE; Dinner, S; Dunn, TJ; Gotlib, J; Hao, Y; Liedtke, M; Medeiros, BC; Price, E1
Ahn, JS; Cho, MS; Jung, SH; Jung, SY; Kim, HJ; Kim, YK; Lee, JJ; Lee, SS; Yang, DH1

Reviews

2 review(s) available for 10-propargyl-10-deazaaminopterin and bortezomib

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016
Novel agents in development for peripheral T-cell lymphoma.
    Seminars in hematology, 2010, Volume: 47 Suppl 1

    Topics: Aminopterin; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Clinical Trials as Topic; Depsipeptides; Drug Design; Drugs, Investigational; Histone Deacetylase Inhibitors; Humans; Immunologic Factors; Lenalidomide; Lymphoma, T-Cell, Peripheral; Purine Nucleosides; Pyrazines; Pyrimidinones; Salvage Therapy; Thalidomide

2010

Trials

2 trial(s) available for 10-propargyl-10-deazaaminopterin and bortezomib

ArticleYear
Pralatrexate pharmacology and clinical development.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, Dec-15, Volume: 19, Issue:24

    Topics: Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Boronic Acids; Bortezomib; Deoxycytidine; Depsipeptides; Disease-Free Survival; Drug Approval; Drug Synergism; Gemcitabine; Humans; Lymphoma, T-Cell; Male; Pyrazines; Treatment Outcome; United States; United States Food and Drug Administration

2013
A phase 1, open-label, dose-escalation study of pralatrexate in combination with bortezomib in patients with relapsed/refractory multiple myeloma.
    British journal of haematology, 2016, Volume: 173, Issue:2

    Topics: Aged; Aminopterin; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Dose-Response Relationship, Drug; Female; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Multiple Myeloma; Neoplasm Recurrence, Local; Treatment Outcome

2016

Other Studies

3 other study(ies) available for 10-propargyl-10-deazaaminopterin and bortezomib

ArticleYear
Pralatrexate is synergistic with the proteasome inhibitor bortezomib in in vitro and in vivo models of T-cell lymphoid malignancies.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-15, Volume: 16, Issue:14

    Topics: Aminopterin; Animals; Apoptosis; Boronic Acids; Bortezomib; Caspase 8; Caspase 9; Cell Line, Tumor; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Humans; Lymphoma, T-Cell; Mice; Mice, SCID; Neoplasm Transplantation; Pyrazines; Xenograft Model Antitumor Assays

2010
Choosing a systemic treatment for advanced stage cutaneous T-cell lymphoma: mycosis fungoides and Sézary syndrome.
    Hematology. American Society of Hematology. Education Program, 2015, Volume: 2015

    Topics: Alemtuzumab; Aminopterin; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bortezomib; Clinical Trials as Topic; Deoxycytidine; Depsipeptides; Diphtheria Toxin; Disease Progression; Doxorubicin; Electrons; Gemcitabine; Humans; Hydroxamic Acids; Immunotherapy; Incidence; Interleukin-2; Lenalidomide; Lymphoma, T-Cell; Mycosis Fungoides; Pentostatin; Photopheresis; Polyethylene Glycols; Randomized Controlled Trials as Topic; Recombinant Fusion Proteins; Retinoids; Sezary Syndrome; Stem Cell Transplantation; Thalidomide; United States; Vorinostat

2015
Pralatrexate in Combination with Bortezomib for Relapsed or Refractory Peripheral T Cell Lymphoma in 5 Elderly Patients.
    Journal of Korean medical science, 2016, Volume: 31, Issue:7

    Topics: Aged; Aminopterin; Antineoplastic Agents; Bortezomib; Drug Administration Schedule; Drug Therapy, Combination; Humans; Lymphoma, T-Cell, Peripheral; Male; Neoplasm Recurrence, Local; Neutropenia; Positron Emission Tomography Computed Tomography

2016